Publications by authors named "S Krag"
Fifteen percent of all colorectal cancers have detectable defects in the mismatch repair system (dMMR). MMR status is used to identify possible Lynch Syndrome (LS) and to determine prognosis and choice of treatment. Two standard techniques for determining MMR status are immunohistochemistry (IHC) and analysis for microsatellite instability (MSI) by PCR.
View Article and Find Full Text PDFAcute kidney injury (AKI) is an important risk factor for chronic kidney disease (CKD), but the underlying mechanisms of failed tubule repair and AKI-CKD transition are incompletely understood. In this study, we aimed for dynamic tracking of tubule injury and remodeling to understand if focal injury upon AKI may spread over time. Here, we present a model of AKI, in which we rendered only half of the kidney ischemic.
View Article and Find Full Text PDFWe describe the case of a 24-year-old male patient with multiple sclerosis (MS) who was treated with Teriflunomide for eight months. However, due to MS progression, treatment was switched to Ocrelizumab. After 15 months of therapy with Ocrelizumab the patient developed edema and nephrotic-range albuminuria.
View Article and Find Full Text PDFBackground: Living kidney donors (LKDs) are at increased risk of chronic kidney disease, whereas transplant recipients experience progressive reduction of graft function. We examined the predictive value of quantitative stereology on renal function in LKDs and recipients of living donor kidneys, based on perioperative biopsies from the donated kidney.
Methods: Cortex volume of both donor kidneys was determined by contrast-enhanced computed tomography and single-kidney glomerular filtration rate (GFR) by 51 chrome-EDTA clearance together with renography.
Article Synopsis
- Diabetic nephropathy (DN) is a major complication of diabetes leading to kidney failure, and the role of insulin-like growth factor (IGF) signaling in DN is not well understood.
- The study found that PAPP-A (a protein that activates IGF) and its inhibitors (STC1 and STC2) are present in human kidneys and that an increase in active PAPP-A is linked to DN severity.
- Targeting PAPP-A activity could be a potential new treatment approach for DN, as it appears that balance between PAPP-A and STCs is critical for kidney health.